Drug Profile
Research programme: nucleoside prodrug therapeutics - Nascent
Alternative Names: NP 50501; NP 50512Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nascent Pharmaceuticals
- Class Nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 20 Jun 2005 Preclinical trials in Cancer in USA (PO)